Literature DB >> 11266289

Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.

P Brown1, R G Will, R Bradley, D M Asher, L Detwiler.   

Abstract

The epidemic of bovine spongiform encephalopathy (BSE) in the United Kingdom, which began in 1986 and has affected nearly 200,000 cattle, is waning to a conclusion, but leaves in its wake an outbreak of human Creutzfeldt-Jakob disease, most probably resulting from the consumption of beef products contaminated by central nervous system tissue. Although averaging only 10-15 cases a year since its first appearance in 1994, its future magnitude and geographic distribution (in countries that have imported infected British cattle or cattle products, or have endogenous BSE) cannot yet be predicted. The possibility that large numbers of apparently healthy persons might be incubating the disease raises concerns about iatrogenic transmissions through instrumentation (surgery and medical diagnostic procedures) and blood and organ donations. Government agencies in many countries continue to implement new measures to minimize this risk.

Entities:  

Mesh:

Year:  2001        PMID: 11266289      PMCID: PMC2631690          DOI: 10.3201/eid0701.010102

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  37 in total

1.  Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.

Authors:  J Huillard d'Aignaux; D Costagliola; J Maccario; T Billette de Villemeur; J P Brandel; J P Deslys; J J Hauw; J L Chaussain; Y Agid; D Dormont; A Alpérovitch
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

2.  Immunohistochemical evaluation of tonsillar tissue for preclinical screening of scrapie based on surveillance in Belgium.

Authors:  S Roels; E Vanopdenbosch; J P Langeveld; B E Schreuder
Journal:  Vet Rec       Date:  1999-10-30       Impact factor: 2.695

Review 3.  The risk of bovine spongiform encephalopathy ('mad cow disease') to human health.

Authors:  P Brown
Journal:  JAMA       Date:  1997-09-24       Impact factor: 56.272

4.  Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans.

Authors:  M R Scott; R Will; J Ironside; H O Nguyen; P Tremblay; S J DeArmond; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  Decontamination of Creutzfeldt-Jakob disease and other transmissible agents.

Authors:  L Manuelidis
Journal:  J Neurovirol       Date:  1997-02       Impact factor: 2.643

Review 6.  BSE: a decade on--Part I.

Authors:  J G Collee; R Bradley
Journal:  Lancet       Date:  1997-03-01       Impact factor: 79.321

7.  Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy.

Authors:  M J Schmerr; A L Jenny; M S Bulgin; J M Miller; A N Hamir; R C Cutlip; K R Goodwin
Journal:  J Chromatogr A       Date:  1999-08-20       Impact factor: 4.759

8.  Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans.

Authors:  P Brown; L Cervenáková; L M McShane; P Barber; R Rubenstein; W N Drohan
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

9.  Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent.

Authors:  M E Bruce; R G Will; J W Ironside; I McConnell; D Drummond; A Suttie; L McCardle; A Chree; J Hope; C Birkett; S Cousens; H Fraser; C J Bostock
Journal:  Nature       Date:  1997-10-02       Impact factor: 49.962

Review 10.  BSE: a decade on--Part 2.

Authors:  J G Collee; R Bradley
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

View more
  31 in total

Review 1.  Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease.

Authors:  P Brown
Journal:  BMJ       Date:  2001-04-07

2.  Risks of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in the United States.

Authors:  Richard T Johnson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-03       Impact factor: 5.081

3.  Communication and miscommunication of risk: understanding UK parents' attitudes to combined MMR vaccination.

Authors:  Paul Bellaby
Journal:  BMJ       Date:  2003-09-27

4.  [Variant Creutzfeldt-Jakob disease. Epidemiology, detection, diagnosis and prevention with special reference to minimizing risk of iatrogenic transmission by medical products, especially surgical instruments. Report of the Variant Creutzfeldt-Jakob Disease Task Force on this topic].

Authors: 
Journal:  HNO       Date:  2002-04       Impact factor: 1.284

Review 5.  Blood transfusion medicine.

Authors:  Fiona Regan; Clare Taylor
Journal:  BMJ       Date:  2002-07-20

6.  BSE safety standards: An evaluation of public health policies of Japan, Europe, and USA.

Authors:  Gino C Matibag; Manabu Igarashi; Hiko Tamashiro
Journal:  Environ Health Prev Med       Date:  2005-09       Impact factor: 3.674

7.  Use of a marker organism to model the spread of central nervous system tissue in cattle and the abattoir environment during commercial stunning and carcass dressing.

Authors:  D J Daly; D M Prendergast; J J Sheridan; I S Blair; D A McDowell
Journal:  Appl Environ Microbiol       Date:  2002-02       Impact factor: 4.792

Review 8.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

9.  Serum-free solutions for cryopreservation of cells.

Authors:  Lia H Campbell; Kelvin G M Brockbank
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-09-19       Impact factor: 2.416

10.  Human prion diseases in the United States.

Authors:  Robert C Holman; Ermias D Belay; Krista Y Christensen; Ryan A Maddox; Arialdi M Minino; Arianne M Folkema; Dana L Haberling; Teresa A Hammett; Kenneth D Kochanek; James J Sejvar; Lawrence B Schonberger
Journal:  PLoS One       Date:  2010-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.